Given that a low CD4+/CD8+ ratio is predictive of adverse clinical outcomes in PLWH, it could serve as a potential tool for evaluating the course of COVID-19 in these patients, thus providing an additional option in risk stratification [116,117]. The gene discussed is CD4; the disease is COVID-19.